BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 32090349)

  • 1. Comparison of Body Size, Morphomics, and Kidney Function as Covariates of High-Dose Methotrexate Clearance in Obese Adults with Primary Central Nervous System Lymphoma.
    Pai MP; Debacker KC; Derstine B; Sullivan J; Su GL; Wang SC
    Pharmacotherapy; 2020 Apr; 40(4):308-319. PubMed ID: 32090349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urine volume to hydration volume ratio is associated with pharmacokinetics of high-dose methotrexate in patients with primary central nervous system lymphoma.
    Isono T; Hira D; Morikochi A; Fukami T; Ueshima S; Nozaki K; Terada T; Morita SY
    Pharmacol Res Perspect; 2021 Dec; 9(6):e00883. PubMed ID: 34664791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas.
    Ferreri AJ; Guerra E; Regazzi M; Pasini F; Ambrosetti A; Pivnik A; Gubkin A; Calderoni A; Spina M; Brandes A; Ferrarese F; Rognone A; Govi S; Dell'Oro S; Locatelli M; Villa E; Reni M
    Br J Cancer; 2004 Jan; 90(2):353-8. PubMed ID: 14735176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population Pharmacokinetics of High-Dose Methotrexate in Patients With Primary Central Nervous System Lymphoma.
    Mei S; Li X; Jiang X; Yu K; Lin S; Zhao Z
    J Pharm Sci; 2018 May; 107(5):1454-1460. PubMed ID: 29331383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial.
    Joerger M; Huitema AD; Krähenbühl S; Schellens JH; Cerny T; Reni M; Zucca E; Cavalli F; Ferreri AJ
    Br J Cancer; 2010 Feb; 102(4):673-7. PubMed ID: 20125159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of methotrexate exposure on outcome in patients treated with MBVP chemotherapy for primary central nervous system lymphoma.
    Blasco H; Senecal D; Le Gouge A; Pinard E; Benz-de Bretagne I; Colombat P; Hulot JS; Chatelut E; Le Guellec C
    Br J Clin Pharmacol; 2010 Sep; 70(3):367-75. PubMed ID: 20716237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of polyglutamylation in primary central nervous system lymphoma.
    Shinojima N; Fujimoto K; Makino K; Todaka K; Yamada K; Mikami Y; Oda K; Nakamura K; Jono H; Kuratsu JI; Nakamura H; Yano S; Mukasa A
    Acta Neuropathol Commun; 2018 Feb; 6(1):15. PubMed ID: 29475458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL).
    Bergner N; Monsef I; Illerhaus G; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2012 Nov; 11():CD009355. PubMed ID: 23152274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma?
    Khan RB; Shi W; Thaler HT; DeAngelis LM; Abrey LE
    J Neurooncol; 2002 Jun; 58(2):175-8. PubMed ID: 12164690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic value of serum methotrexate area under curve in elderly primary CNS lymphoma patients.
    Kasenda B; Rehberg M; Thürmann P; Franzem M; Veelken H; Fritsch K; Schorb E; Finke J; Lebiedz D; Illerhaus G
    Ann Hematol; 2012 Aug; 91(8):1257-64. PubMed ID: 22456893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. White matter changes in primary central nervous system lymphoma patients treated with high-dose methotrexate with or without rituximab.
    Estephan F; Ye X; Dzaye O; Wagner-Johnston N; Swinnen L; Gladstone DE; Ambinder R; Kamson DO; Lambrecht S; Grossman SA; Lin DDM; Holdhoff M
    J Neurooncol; 2019 Dec; 145(3):461-466. PubMed ID: 31621040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetics of methotrexate in paediatric patients with acute lymphoblastic leukaemia and malignant lymphoma.
    Zhan M; Sun Y; Zhou F; Wang H; Chen Z; Yan L; Li X
    Xenobiotica; 2022 Mar; 52(3):265-273. PubMed ID: 35446233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective evaluation of high-dose methotrexate pharmacokinetics in adult patients with lymphoma using novel determinants of kidney function.
    Barreto JN; Reid JM; Thompson CA; Mara KC; Rule AD; Kashani KB; Leung N; Larson TR; McGovern RM; Witzig TE; Barreto EF
    Clin Transl Sci; 2022 Jan; 15(1):105-117. PubMed ID: 34378331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carboxypeptidase G2 rescue after high-dose methotrexate.
    DeAngelis LM; Tong WP; Lin S; Fleisher M; Bertino JR
    J Clin Oncol; 1996 Jul; 14(7):2145-9. PubMed ID: 8683248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and pharmacogenetics of high-dose methotrexate in Chinese adult patients with non-Hodgkin lymphoma: a population analysis.
    Yang L; Wu H; de Winter BCM; Sheng CC; Qiu HQ; Cheng Y; Chen J; Zhao QL; Huang J; Jiao Z; Xie RX
    Cancer Chemother Pharmacol; 2020 May; 85(5):881-897. PubMed ID: 32246190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delayed methotrexate elimination in a patient with primary central nervous system lymphoma: A case report.
    Urata S; Yoshikawa N; Saito K; Tazaki T; Ohno R; Takeshima H; Ikeda R
    J Clin Pharm Ther; 2021 Dec; 46(6):1796-1799. PubMed ID: 34008211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early recognition of patients with decreased methotrexate clearance following high-dose methotrexate infusion therapy.
    Ikeda H; Kihira K; Kuwata N; Arai S; Kimura Y; Miyake K; Kitaura T; Fujimura K; Kuramoto A; Fukuchi H
    Hiroshima J Med Sci; 1996 Jun; 45(2):57-62. PubMed ID: 8810132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic impact of completion of initial high-dose methotrexate therapy on primary central nervous system lymphoma: a single institution experience.
    Makino K; Nakamura H; Hide T; Kuroda J; Yano S; Kuratsu J
    Int J Clin Oncol; 2015 Feb; 20(1):29-34. PubMed ID: 24722885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calculated versus measured creatinine clearance for dosing methotrexate in the treatment of primary central nervous system lymphoma.
    Gerber DE; Grossman SA; Batchelor T; Ye X
    Cancer Chemother Pharmacol; 2007 May; 59(6):817-23. PubMed ID: 16972068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical utility and pharmacology of high-dose methotrexate in the treatment of primary CNS lymphoma.
    Green MR; Chowdhary S; Lombardi KM; Chalmers LM; Chamberlain M
    Expert Rev Neurother; 2006 May; 6(5):635-52. PubMed ID: 16734512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.